- Trial status: Closed to recruitment in the UK
- Trial ID: NCT06380335
What is OPAL?
OPAL is an observational study sponsored by Resolution Therapeutics. 11 hospitals across England and Scotland are participating in the study.
OPAL stands for Observational Study in PArticipants with Liver Cirrhosis.
What is an observational study?
An observational study is a type of clinical trial.
The medical condition of participants is observed, and health information is recorded over a fixed period of time.
People taking part will continue to receive the current standard medical care. But there is no new medicine or treatment being tested.
Find out more about observational studies from the UCL website
What is the reason for OPAL?
Advanced cirrhosis can progress in different ways for different people. We do not fully understand how the disease develops after someone has their first liver decompensation event.
What is a liver decompensation event?
Even if you have cirrhosis, your liver can carry on doing its many important jobs.
Liver decompensation is when the liver stops working properly. This can result in symptoms that need urgent medical attention. Such as ascites, hepatic encephalopathy, or variceal bleed.
How could OPAL help?
The OPAL trial will collect data from routine hospital visits, medical records, and blood tests. This data will help doctors and scientists understand how to better care for people with advanced cirrhosis.
The research will also help companies developing new medicines and treatments. OPAL is sponsored by a company called Resolution Therapeutics.
This is an innovative biotech company with labs in Edinburgh and London. They are working on developing a novel treatment for advanced cirrhosis. The data collected in OPAL will help with future studies of their new treatment. If you decide to participate in OPAL, you would be contributing to medical research that may lead to improved treatments for people like you.
Taking part in the OPAL study
Can I take part in OPAL?
OPAL is focused on people with “decompensated cirrhosis”. This study is no longer looking for additional participants to join.
There are currently 11 hospitals across England and Scotland participating in the study and participants enrolled in the study are in the follow up period.
